Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models

Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models

Background: Previous studies have suggested that patients with HER2-low breast cancers do not benefit from trastuzumab treatment although the reasons remain unclear. Methods: We investigated the effect of trastuzumab monotherapy and its combination with different HER2 targeting treatments in a panel...

書誌詳細
主要な著者:	Arshad, M, Azad, A, Chan, PYK, Vigneswara, V, Feldinger, K, Nafi, SNM, Laporte-Maguire, E, De Santo, C, Zuo, J, Shaaban, AM, Kong, A
フォーマット:	Journal article
言語:	English
出版事項:	Springer Nature [academic journals on nature.com] 2024

類似資料

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
著者:: Jamunarani Veeraraghavan, 等
出版事項: (2021-05-01)

Profile of neratinib and its potential in the treatment of breast cancer
著者:: Feldinger K, 等
出版事項: (2015-06-01)

Exceptional disease control with neratinib monotherapy in HER2-positive advanced breast cancer: A case report
著者:: Pierluigi di Mauro, 等
出版事項: (2022-06-01)

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
著者:: Samuel A. Jacobs, 等
出版事項: (2019-12-01)

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
著者:: Abul Azad, 等
出版事項: (2025-01-01)

Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer
著者:: Iwata, Hiroji, 等
出版事項: (2019)

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
著者:: Samuel A. Jacobs, 等
出版事項: (2020-01-01)

Neratinib for HER2-positive breast cancer with an overlooked option
著者:: Liting Guo, 等
出版事項: (2023-10-01)

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
著者:: Ünal Metin Tokat, 等
出版事項: (2025-01-01)

Assessing the role of ADAM10 in Trastuzumab treatment and resistance
著者:: Feldinger, K
出版事項: (2012)

The role of HER4 in relation to trastuzumab resistance and prognosis in HER2 positive breast cancer
著者:: Mohd Nafi, SN
出版事項: (2014)

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
著者:: Sara Alkhezayem, 等
出版事項: (2020-08-01)

Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma
著者:: Martina Napolitano, 等
出版事項: (2025-01-01)

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
著者:: Samuel A. Jacobs, 等
出版事項: (2024-04-01)

Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer
著者:: Inés Romero-Pérez, 等
出版事項: (2024-08-01)

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
著者:: James J. Harding, 等
出版事項: (2023-02-01)

Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
著者:: Samuel A. Jacobs, 等
出版事項: (2024-05-01)

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
著者:: Sabine Schmid, 等
出版事項: (2019-09-01)

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo
著者:: Neil T Conlon, 等
出版事項: (2024-11-01)

Metastatic Salivary Duct Carcinoma with ERBB2 Amplification and Sequential Response to Ado-Trastuzumab Emtansine and Neratinib: A Case Report
著者:: Nora Asper, 等
出版事項: (2023-11-01)

Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib : implications for the treatment of HER2-positive and HER2-mutated breast cancer
著者:: Collins, Denis M., 等
出版事項: (2020)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
著者:: Baubek Spanov, 等
出版事項: (2022-01-01)

Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients
著者:: Mamdouh Ramadan, 等
出版事項: (2020-01-01)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
著者:: Laurence Booth, 等
出版事項: (2019-07-01)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
著者:: Alena Rudkouskaya, 等
出版事項: (2020-12-01)

Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib
著者:: Stephanie N. Shishido, 等
出版事項: (2022-02-01)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
著者:: Lanqi Ren, 等
出版事項: (2023-08-01)

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
著者:: Chilà G, 等
出版事項: (2021-06-01)

Dramatic Clinical Response of Relapsed Metastatic Extramammary Paget’s Disease to Trastuzumab Monotherapy
著者:: S. Wakabayashi, 等
出版事項: (2012-01-01)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
著者:: Jiangping Yang, 等
出版事項: (2022-09-01)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
著者:: Jangsoon Lee, 等
出版事項: (2021-06-01)

Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report
著者:: Ayaka Isogai, 等
出版事項: (2023-06-01)

Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition
著者:: Evan DuBose, 等
出版事項: (2024-05-01)

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
著者:: Sietske B.M. Gaykema, 等
出版事項: (2014-07-01)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
著者:: Izzet Dogan, 等
出版事項: (2023-05-01)

Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer
著者:: Yi-Tsung Yang, 等
出版事項: (2014-12-01)

Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
著者:: Negar Pourjamal, 等
出版事項: (2025-03-01)

Cost-minimization analysis comparing subcutaneous trastuzumab at home with intravenous trastuzumab for HER2-positive breast cancer in Singapore
著者:: Yanting Ouyang, 等
出版事項: (2024-11-01)

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
著者:: Shuhui You, 等
出版事項: (2023-12-01)

Aggressive HER2-Positive Gastric Cancer in a Young Patient, Refractory in Trastuzumab and Progressive with Trastuzumab-Emtansine Treatment
著者:: Vildana Goga Çmega, 等
出版事項: (2024-03-01)